Galmed Pharmaceuticals Ltd. (GPH)
XFRA 
NASDAQ (CM) Primary XFRA Summary
GPH Chart
Galmed Pharma Surges 400%: What's Behind the Explosion?
Galmed Pharmaceuticals NASDAQ: GLMD, a little-known biotech stock, has become the center of attention as its shares have skyrocketed close to 400%. By 2 pm, the stock had traded over 80 million shares, a monumental leap from its average daily volume of just 75,000.
Galmed Pharmaceuticals Ltd. (GPH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Galmed Pharmaceuticals Ltd. ever had a stock split?
Galmed Pharmaceuticals Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Allen Baharaff CEO | XFRA Exchange | IL0011313900 ISIN |
| IL Country | 3 Employees | - Last Dividend | 30 Aug 2024 Last Split | 13 Mar 2014 IPO Date |
Overview
Galmed Pharmaceuticals Ltd. is a biopharmaceutical company established in 2000 and based in Tel Aviv, Israel, focusing on the development and commercialization of novel therapeutics for the treatment of liver diseases. The company's primary objective is to advance the clinical development of its flagship product, Aramchol, along with other innovative treatments targeted at liver health issues, including non-alcoholic steato-hepatitis (NASH) among other conditions. Galmed's strategic partnerships and licensing agreements, such as with Samil Pharma. Co., Ltd., and collaboration with OnKai for AI platform utilization, underscore its commitment to enhancing its product offering and expanding its market presence.
Products and Services
- Aramchol
- ARRIVE Study
- Amilo-5MER
Aramchol is Galmed's leading candidate, currently in a Phase III clinical study. This orally administered therapy is designed for the treatment of non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have pre-diabetes or type-II diabetes mellitus. Aramchol’s mechanism targets liver fat metabolism, which plays a crucial role in addressing this increasingly common liver disease.
ARRIVE Study represents Galmed's Phase IIa clinical trial efforts with Aramchol, focusing beyond NASH to other related conditions. This study evaluates the effectiveness of Aramchol in treating HIV-associated non-alcoholic fatty liver disease and lipodystrophy, indicating the company’s initiative to extend Aramchol’s therapeutic implications.
Amilo-5MER is a synthetic peptide composed of 5 amino acids: methionine, threonine, alanine, aspartic acid, and valine. Being developed by Galmed, this innovative compound signifies the company's exploration into new therapeutics aimed at treating liver diseases through unique mechanisms.
